U.S. patent application number 10/918234 was filed with the patent office on 2005-05-05 for stimulation for delivery of molecular therapy.
This patent application is currently assigned to Medtronic, Inc.. Invention is credited to Deno, D. Curtis, Donovan, Maura G., Fernandes, Brian C.A., Mulligan, Lawrence J., Soykan, Orhan.
Application Number | 20050096701 10/918234 |
Document ID | / |
Family ID | 26882894 |
Filed Date | 2005-05-05 |
United States Patent
Application |
20050096701 |
Kind Code |
A1 |
Donovan, Maura G. ; et
al. |
May 5, 2005 |
Stimulation for delivery of molecular therapy
Abstract
The present invention provides a novel stimulatory device for
the controlled production of angiogenic growth factors. More
specifically, the present invention provides a subthreshold pulse
generator for the local production of vascular endothelial growth
factor.
Inventors: |
Donovan, Maura G.; (St.
Paul, MN) ; Soykan, Orhan; (Houghton, MI) ;
Deno, D. Curtis; (Andover, MN) ; Mulligan, Lawrence
J.; (Andover, MN) ; Fernandes, Brian C.A.;
(Roseville, MN) |
Correspondence
Address: |
Kenneth J. Collier
Medtronic, Inc.
710 Medtronic Parkway N.E.
Minneapolis
MN
55432
US
|
Assignee: |
Medtronic, Inc.
|
Family ID: |
26882894 |
Appl. No.: |
10/918234 |
Filed: |
August 13, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10918234 |
Aug 13, 2004 |
|
|
|
09799304 |
Mar 5, 2001 |
|
|
|
6810286 |
|
|
|
|
60187280 |
Mar 6, 2000 |
|
|
|
Current U.S.
Class: |
607/2 |
Current CPC
Class: |
A61N 1/326 20130101 |
Class at
Publication: |
607/002 |
International
Class: |
A61N 001/00 |
Claims
What is claimed is:
1. A subthreshold pulse generator comprising: a.) a power supply;
and b a control mechanism interconnected with the power supply to
deliver a subthreshold pulse to a targeted cell or tissues wherein
the subthreshold stimulus is less than or equal to about 1
volt.
2. A subthreshold pulse generator of claim 1, wherein the control
mechanism controls at least one additional set of components
selected from a stimulus timer, output amplitude control, charge
balanced pulse timer, stimulation threshold monitor, and a lead
continuity monitor.
3. A subthreshold pulse generator of claim 1, wherein the control
mechanism has at least one additional set of components selected
from a stimulus timer, output amplitude control, charge balanced
pulse timer, stimulation threshold monitor, and a lead continuity
monitor.
4. A subthreshold pulse generator of claim 1 wherein the the power
supply provides either a constant or variable voltage.
5. A subthreshold pulse generator of claim 1 wherein the amplitude
of the delivery of the electrical pulse from the power supply has
an electrical field of about 1 V/cm.
6. A subthreshold pulse generator of claim 1 wherein the amplitude
of the delivery of the electrical pulse from the power supply has
an electrical field of about 0.5 V/cm.
7. A subthreshold pulse generator of claim 1 wherein the amplitude
of the delivery of the electrical pulse from the power supply has
electrical field of about 0.1 V.
8. A subthreshold pulse generator of any one of claims 5, 6, or 7
wherein the electrical field is .+-.about 30%.
9. A subthreshold pulse generator of any one of claims 5, 6, or 7
wherein the electrical field is .+-.about 20%.
10. A subthreshold pulse generator of any one of claims 5, 6, or 7
wherein the variable electrical field is .+-.about 10%.
11. A subthreshold pulse generator of any one of claims 5, 6, or 7
wherein the variable electrical field is .+-.about 5%.
12. A subthreshold pulse generator of claim 1 wherein the
stimulation period of the subthreshold pulse from the power supply
is less than about 20 msec.
13. A subthreshold pulse generator of claim 1 wherein the
stimulation period of the subthreshold pulse from the power supply
is less than about 10 msec,
14. A subthreshold pulse generator of claim 1 wherein the
stimulation period of the subthreshold pulse from the power supply
is less than about 5 msec.
15. A subthreshold pulse generator of claim 1 wherein the
stimulation period of the subthreshold pulse from the power supply
is less than about 1 msec.
16. A subthreshold pulse generator of claim 1 wherein the
stimulation period of the subthreshold pulse from the power supply
is less than about 0.3 msec.
17. A subthreshold pulse generator of claim 1 wherein the frequency
of stimulation is about 10 Hz.
18. A subthreshold pulse generator of claim 1 wherein the frequency
of stimulation is about 25 Hz.
19. A subthreshold pulse generator of claim 1 wherein the frequency
of stimulation is about 40 Hz.
20. A subthreshold pulse generator of claim 1 wherein the frequency
of stimulation is about 50 Hz.
21. A subthreshold pulse generator of claim 1 wherein the frequency
of stimulation is about 70 Hz.
22. A subthreshold pulse generator of claim 1 wherein the frequency
of stimulation is about 85 Hz.
23. A subthreshold pulse generator of claim 1 wherein the frequency
of stimulation is about 100 Hz.
24. A subthreshold pulse generator of claim 1, further comprising a
plurality of electrodes for delivery of said subthreshold pulse to
the targeted cells or tissue.
25. A subthreshold pulse generator of claim 1, further comprising
at least one electrode is capable of being placed on a catheter and
delivered to a target organ transluminally.
26. A subthreshold pulse generator of claim 1, wherein the
subthreshold pulse generator provides stimulation to the cells or
tissue when the electrodes are in contact with or in proximity of
the targeted cells or tissue.
27. A subthreshold pulse generator of claim 1, wherein the
amplitude and duration period of the delivery is sufficient to
stimulate angiogensis.
28. A subthreshold pulse generator of claim 1, wherein the
delivered subthreshold pulse is charge balanced.
29. A subthreshold pulse generator of claim 1, additionally
comprising a computer processing unit in electronic communication
with the power supply, the computer being programmable to cause the
subthreshold pulse generator to deliver a predetermined amount of
electrical current or voltage over a predetermined period of
delivery to said targeted cells or tissue.
30. A subthreshold pulse generator of claim 1, wherein the
electrical pulse generator is implanted in the body.
31. A subthreshold pulse generator of claim 1, wherein the
electrical pulse generator is external to the body.
32. A subthreshold pulse generator of claim 1, for delivering an
electrical field over a predetermined period of time to a targeted
tissue or cell to stimulate the production of VEGF expression.
33. A subthreshold pulse generator of claim 1, wherein the
electrical pulse generator is externally controlled.
34. A therapeutic delivery system comprising a subthreshold pulse
generator of claim 1, operably linked with mammalian cells or
tissue.
35. A therapeutic delivery system of claim 34 wherein the
subthreshold pulse generator provides a subthreshold
stimulation.
36. A therapeutic delivery system of claim 34 further comprising a
plurality of electrodes wherein the subthreshold pulse generator
provides stimulation to the cells or tissue from a plurality of
electrodes.
37. A therapeutic delivery system of claim 34 wherein the
electrical pulse generator provides stimulation to the cell or
tissue when the electrodes are in contact with or in proximity of
the targeted cells or tissue.
38. A therapeutic delivery system of one of claims 34-37 wherein
the stimulated tissue is muscle tissue.
39. A therapeutic delivery system of one of claims 34-37 wherein
the stimulated tissue is heart muscle tissue.
40. A therapeutic delivery system of one of claims 34-37 wherein
the stimulated tissue is skeletal muscle tissue.
41. A therapeutic delivery system of one of claims 34-37 wherein
the stimulated cells are smooth muscle cells.
42. A therapeutic delivery system one of claims 34-37 wherein the
stimulated cells are vascular muscle cells.
43. A therapeutic delivery system of one of claims 34-37 wherein
the stimulated cells are vascular endothelial cells.
44. A therapeutic delivery system of claim 37 wherein the
electrodes are configured in a manner selected from the group
consisting of unipolar, bipolar, and multiple electrode
configurations.
45. A therapeutic delivery system of claim 34 wherein the
electrical pulse generator is implanted.
46. A therapeutic delivery system of claim 34 wherein the
electrical pulse generator is external.
47. A therapeutic delivery system of claim 34 wherein the
electrical pulse generator is externally controlled.
48. A therapeutic delivery system of claim 34 additionally
comprising a sensing electrode for optionally readjusting or
synchronizing the period of delivery of the subthreshold
pulses.
49. A therapeutic delivery system of claim 34 for delivering an
electrical field over a predetermined period of time to targeted
cells or tissue to stimulate the production of VEGF expression.
50. A method of treating a patient comprising providing the patient
with a subthreshold pulse generator operably linked with targeted
mammalian cells or tissues wherein the subthreshold pulse generator
comprises (a) a power supply; and (b) a control mechanism
interconnected with the power supply to deliver a subthreshold
pulse to a targeted cell or tissue wherein the threshold stimulus
is less than or equal to about 1 volt.
51. A method of treating a patient comprising providing the patient
with a subthreshold pulse generator operably linked to the tissue
for acute subthreshold stimulation therapy to improve angiogenesis;
wherein the subthreshold pulse generator comprises (a) a power
supply; and (b) a control mechanism interconnected with the power
supply to deliver a subthreshold pulse to a targeted cell or tissue
wherein the subthreshold stimulus is less than or equal to about 1
volt.
52. A method of treating a patient comprising using the pulse
generator of claim 1 for delivering an electrical field over a
predetermined period of time to a targeted cells or tissue to
stimulate the production of VEGF expression.
53. A method of increasing vascularization in a target tissue
comprising providing subthreshold stimulatory pulses to the
targeted muscle tissue using a subthreshold pulse generator:
wherein the subthreshold pulse generator comprises (a) a power
supply; and (b) a control mechanism interconnected with the power
supply to deliver a subthreshold pulse to a targeted cell or tissue
wherein the subthreshold stimulus is less than or equal to about 1
volt.
54. A method of increasing vascularization in a target tissue
wherein the subthreshold stimulatory pulses are targeted to
vascular muscle tissue using a subthreshold pulse generator;
wherein the subthreshold pulse generator comprises (a) a power
supply; and (b) a control mechanism interconnected with the power
supply to deliver a subthreshold pulse to a targeted cell or tissue
wherein the subthreshold stimulus is less than or equal to about 1
volt.
55. A method of increasing vascularization in a target tissue
wherein the subthreshold stimulatory pulses are targeted to heart
muscle tissue using a subthreshold pulse generator; wherein the
subthreshold pulse generator comprises (a) a power supply; and (b)
a control mechanism interconnected with the power supply to deliver
a subthreshold pulse to a targeted cell or tissue wherein the
subthreshold stimulus is less than or equal to about 1 volt.
56. A method of increasing vascularization in a target tissue
wherein the subthreshold stimulatory pulses are targeted to
skeletal muscle tissue using a subthreshold pulse generator;
wherein the subthreshold pulse generator comprises (a) a power
supply; and (b) a control mechanism interconnected with the power
supply to deliver a subthreshold pulse to a targeted cell or tissue
wherein the subthreshold stimulus is less than or equal to about 1
volt.
57. A method of treating a patient comprising providing the patient
with a subthreshold pulse generator operably linked to a muscle
tissue for subthreshold stimulation therapy using a subthreshold
pulse generator; wherein the subthreshold pulse generator comprises
(a) a power supply; and (b) a control mechanism interconnected with
the power supply to deliver a subthreshold pulse to a targeted cell
or tissue wherein the subthreshold stimulus is less than or equal
to about 1 volt.
58. A method of treating a patient of claim 57 wherein stimulated
tissue is muscle tissue.
59. A method of treating a patient of claim 57 wherein stimulated
tissue is heart muscle tissue.
60. A method of treating a patient of claim 57 where in stimulated
tissue is skeletal muscle tissue.
61. A method of treating a patient of claim 57 where in stimulated
cells are muscle cells
62. A method of treating a patient of claim 57 where in stimulated
cells are heart muscle cells.
63. A method of treating a patient of claim 57 where in stimulated
cells are skeletal muscle cells.
64. A method of treating a patient of claim 57 where in stimulated
cells are vascular muscle cells.
65. A method of treating a patient of claim 57 where in stimulated
cells are vascular endothelial cells.
66. A method of improving vascularization in a targeted tissue
comprising the steps of: a. stimulating cultured cells with a
subthreshold electrical field using the pulse generator of claim 1,
and then subsequently b. injecting the stimulated cells into the
targeted body tissue.
67. A method of improving vascularization in a target tissue of
claim 66 wherein the method additionally comprises further
stimulating the injected cells.
68. A method of improving vascularization in a targeted tissue
comprising the steps of: a. injecting cells into a targeted body
tissue; and b. b. stimulating the injected cell area with
subthreshold stimulation using the pulse generator of claim 1.
Description
FIELD OF THE INVENTION
[0001] The present invention provides a novel stimulatory device
for the controlled production of angiogenic growth factors. More
specifically, the present invention provides a subthreshold pulse
generator for the local production of vascular endothelial growth
factor.
BACKGROUND OF THE INVENTION
[0002] Coronary artery disease (CAD) results from arteriosclerosis
of blood vessels serving the heart. Arteriosclerosis is a hardening
and narrowing of the arteries. Often the arteries of the heart can
suddenly become so severely blocked that there is inadequate blood
supply to areas of the heart, leading to the occurrence of a
myocardial infarction. The area of damage where the reduced blood
flow has occurred is called the ischemic area. The ischemic area of
the heart, because it does not get adequate blood flow, is starved
of oxygen and nutrients. This blockage, if not treated quickly, can
lead to severe tissue damage. Often surgical procedures are used to
graft new blood vessels to the ischemic area to improve
circulation. Alternatively, angioplasty or stenting of the blocked
blood vessel is done to reopen or maintain blood flow. However,
by-passing or reopening of the arteries is often not possible
because of limitations of present methodologies and the risk to the
patient from surgical intervention.
[0003] Damage from ischemia from insufficient blood circulation can
also occur in blood vessels peripheral to the heart. Peripheral
arterial occlusive disease (PAOD), caused by arteriosclerosis or by
formation of vascular blood clots from diseases such as diabetes,
often leads to loss of external limbs.
[0004] One way to address the need for improved blood flow to
ischemic tissue is to generate new blood vessels. Angiogenic
factors are known to directly participate in the formation of new
blood vessels. Local administration of recombinant angiogenic
growth factors, such as basic fibroblast growth factor (bFGF) and
vascular endothelial growth factor (VEGF), can salvage ischemic
areas of myocardial and skeletal muscle tissue in animal models. A
number of approaches have been developed to deliver these factors
to ischemic areas in hope of developing new blood vessels,
including direct injection, electroporation, and delivery using
retroviral vectors.
[0005] The direct injection of angiogenic growth factors has many
problems associated with it, most notably problems with effective
delivery of the factors into the cells. Electroporation is a
possible method of delivery of genetic materials encoding
angiogenic factors; however, the transfection efficiency is still
very low and the high-energy pulses directed to the tissue often
kill many healthy cells. Alternatively, others have sought to
develop viral based gene delivery systems to directly produce
angiogenic factors in vivo; however, this approach requires
considerably more development before it is considered to be a safe
and effective therapy. Although extensive research continues in the
areas of gene delivery, very little has been reported on methods to
control and regulate gene expression in vivo. The inability to
effectively deliver the agent to the target tissue, therefore, is
one of the major limitations of the use of such agents. During
delivery of the angiogenic factors the effectiveness is often
destroyed or lost.
[0006] Recent work has been published related to using electrical
fields to stimulate natural production of angiogenic growth
factors. WO 00/27466 describes use of constant voltage sources to
generate electrical fields for stimulating angiogenesis. The
described voltages are on the order of 50-300 volts/cm, which would
also stimulate contractile responses during stimulation.
Stimulation of angiogenesis without causing a contractile muscle
response would be advantageous. In a recent publication
(Circulation, 1999;99:2682-2687) it was reported that low-voltage
electrical stimulation of skeletal muscle induced de novo synthesis
of VEGF protein and promoted angiogenesis. Further work is needed
in this research area. Even with the known methods in the art,
there still exists a need for additional and more effective
subthreshold devices and more efficient methods for the controlled
delivery of angiogenic growth factors to promote angiogenesis in
muscle tissue, and methodologies that can be used to stimulate
angiogenesis in cardiac and vascular tissue.
SUMMARY OF THE INVENTION
[0007] The present invention addresses a number of problems
existing in the prior art with respect to controlled local delivery
of angiogenic factors. Various embodiments of the present invention
provide solutions and to one or more of the problems existing in
the prior art with respect to delivery of angiogenic factors. The
present invention provides a novel electrical pulse generator for
angiogenesis and production angiogenic growth factors.
[0008] The present invention provides an electrical pulse generator
for providing subthreshold pulses. The present device can be
adapted to a range of subthreshold pulses by modulating the time,
frequency, and delivery of a given stimulus. The present generator
allows the use of a constant voltage, regardless of the distance
between electrodes by allowing a variable field density. The
present generator allows for control over the amplitude of the
voltage and for charge balancing of the delivered and recovered
charged pulse.
[0009] In another embodiment, the subthreshold pulse generator can
be used externally, but preferably is designed and configured to be
implantable. The subthreshold pulse generator includes a power
supply and a control mechanism interconnected with the power
supply. Optionally, the pulse generator can be used with a
plurality of electrodes in electrical communication with the power
supply. The present generator is also capable of checking the lead
continuity at a predesignated time.
[0010] The invention also provides a subthreshold pulse generator
for a patient in need thereof. In one aspect, the invention
includes a method for reducing or repairing tissue injury or
disease by providing a means for regulating angiogenic growth
factor production. In another aspect the subthreshold stimulation
provided is sufficient to stimulate angiogenesis in the targeted
body tissue. In yet another aspect, the present invention provides
a novel method of pacing that is capable of stimulating cells or
tissues for the controlled expression of angiogenic factors.
[0011] These and other objects and features of the invention will
become more fully apparent when the following detailed description
is read in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] The following drawings depict certain embodiments of the
invention. They are illustrative only and do not limit the
invention as otherwise disclosed herein.
[0013] FIG. 1: Subthreshold Stimulation of Heart Tissues For
Production of VEGF.
[0014] FIG. 1 is an overview of one mode of operation for
subthreshold stimulation of cardiac tissue.
[0015] FIG. 2: Simplified Schematic of The Output Circuit for
Subthreshold Stimulation
[0016] FIG. 2 illustrates the schematic of the output circuitry of
a subthreshold stimulation device for a pulse generator.
[0017] FIG. 3: Equivalent Circuit of the Subthreshold Stimulation
During the Output Stage
[0018] FIG. 3 illustrates the schematic of the output circuitry of
a subthreshold device for a pulse generator during the output
stage.
[0019] FIG. 4: Subthreshold Stimulation Sequence
[0020] FIG. 4 illustrate a pacing scheme for providing a series of
subthreshold stimulations.
[0021] FIG. 5: Pulse Generator for Subthreshold Stimulation
[0022] FIG. 5 shows a block diagram of a circuit for pulse
generator capable of delivering electrical stimulation to the
target tissue cells.
[0023] FIG. 6: Schematic of The Output Circuit for Subthreshold
Stimulation
[0024] FIG. 6 illustrates the schematic of the output circuitry of
a subthreshold stimulation device for a subthreshold pulse
generator.
[0025] FIG. 7: VEGF Production in Stimulated and Unstimulated
Tissue.
[0026] FIG. 7 shows a western blot of VEGF protein in stimulated
and unstimulated vascular tissue.
DETAILED DESCRIPTION OF THE INVENTION
[0027] Definitions
[0028] "Angiogenic factors" are a group of substances that promote
angiogenesis in a tissue. These factors include, but are not
limited to, vascular endothelial growth factor (VEGF) and
fibroblast growth factor (FGF) and all natural analogs found
encoded in the genome of the patient that are structurally and/or
functionally related members of these factors.
[0029] The term "mature protein" or "mature polypeptide" as used
herein refers to the form(s) of the protein produced by expression
in a mammalian cell. It is generally hypothesized that, once export
of a growing protein chain across the rough endoplasmic reticulum
has been initiated, proteins secreted by mammalian cells have a
signal sequence which is cleaved from the complete polypeptide to
produce a "mature" form of the protein. Often, cleavage of a
secreted protein is not uniform and may result in more than one
species of mature protein. The cleavage site of a secreted protein
is determined by the primary amino acid sequence of the complete
protein and generally cannot be predicted with complete accuracy.
However, cleavage sites for a secreted protein may be determined
experimentally by amino-terminal sequencing of the one or more
species of mature proteins found within a purified preparation of
the protein.
[0030] "Operably coupled" refers to the transference of an
electrical stimulus by a subthreshold pulse generator to a tissue.
A subthreshold pulse generator operably coupled with tissue or
cells refers to a configuration where an electrical stimulus is
delivered to the tissue or cells to cause an increase in available
angiogenic factors. Usually the stimulus is delivered from the
subthreshold pulse generator through leads to electrodes attached
to the tissue.
[0031] The terms "treating", "treatment", and "therapy" as used
herein refer to curative therapy, prophylactic therapy, and
preventive therapy. An example of "preventive therapy" is the
prevention or lessening of a targeted disease or related condition
thereto. For example, subthreshold stimulation can be used
prophylactically to promote angiogenesis as a preventive effort to
avoid the occurrence of a myocardial infarction. Those in need of
treatment include those already with the disease or condition as
well as those prone to having the disease or condition to be
prevented. The terms "treating", "treatment", and "therapy" as used
herein also describe the management and care of a patient for the
purpose of combating a disease or related condition, and includes
the administration of at least one subthreshold electrical pulse to
an ischemic area to improve blood flow to the tissue.
[0032] "Chronic" administration refers to administration of an
electrical stimulus in a continuous mode as opposed to an acute
mode, so as to maintain the initial therapeutic effect (activity)
for an extended period of time.
[0033] "Intermittent" administration is treatment that is not
consecutively done without interruption and is repeated in the
course of time.
[0034] "Ischemia" is defined as an insufficient supply of blood to
a specific organ or tissue. A consequence of decreased blood supply
is an inadequate supply of oxygen and/or nutrients to the organ or
tissue. Prolonged ischemia may result in injury to the affected
organ or tissue. "Anoxia" refers to a virtually complete absence of
oxygen in the organ or tissue, which, if prolonged, may result in
death of the organ or tissue.
[0035] "Ischemic injury" refers to cellular and/or molecular damage
to an organ or tissue as a result of a period of ischemia and/or
ischemia followed by reperfusion.
[0036] "Hypoxic condition" is defined as a condition under which a
particular organ or tissue receives an inadequate supply of
oxygen.
[0037] "Anoxic condition" refers to a condition under which the
supply of oxygen to a particular organ or tissue is cut off.
[0038] "Reperfusion" refers to the resumption of blood flow in a
tissue following a period of ischemia.
[0039] The term "patient" as used herein refers to any mammal,
including humans, domestic and farm animals, and zoo, sports, or
pet animals, such as cattle (e.g., cows), horses, dogs, sheep,
pigs, rabbits, goats, cats, and non-domesticated animals such as
mice and rats. In a preferred embodiment of the invention, the
mammal is a human, dog, rabbit, or mouse.
[0040] A "therapeutically effective amount" as referred to herein
is the minimal amount of subthreshold stimulation that is necessary
to impart a therapeutic benefit or a desired biological effect to a
patient. For example, a "therapeutically effective amount" for a
patient suffering from ischemia is such an amount which induces,
ameliorates, or otherwise causes an improvement in the amount of
angiogenic factors available or otherwise improve circulation in
the tissue. For example, a "therapeutically effective stimulus" is
the amount of electrical stimulation necessary to express a
therapeutically effective amount of an angiogenic protein in an
amount to provide a therapeutic benefit or provides at least one
measurable improvement in circulation.
[0041] The term "pace" as used herein is the act of issuing an
electrical subthreshold stimulus delivered to the cellular tissue
delivered a subthreshold pulse generator. "Pacing" generally refers
to the act of repeatedly issuing an electrical stimulation to the
tissue, as in the present case, delivering a series of subthreshold
stimulations to the tissue.
[0042] "Pharmacologically effective stimulus" is the amount of
stimulus needed to provide a desired level of an angiogenic protein
in the patient. The precise amount of stimulation or pacing needed
will depend upon numerous factors, e.g., such as the specific
angiogenic factor involved, the delivery stimulus employed,
characteristics of stimulus provided, its intended use, and patient
considerations. These determinations can readily be determined by
one skilled in the art in view of the information provided
herein.
[0043] The term "administer an electrical stimulus" means to
deliver electrical stimulation to a tissue. As applied in the
present invention, the electrical stimulus is delivered to the
tissue by a subthreshold pulse generator.
[0044] "Threshold" versus "subthreshold" stimulation refers to a
relative level of applied stimulation. "Threshold" stimulation as
used herein, refers to a level of stimulation to evoke a gross
tissue electrical or mechanical response in the excited tissue,
e.g. the minimum electrical stimulus needed to consistently elicit
a cardiac depolarization for a heart contraction or to elicit a
skeletal muscle movement. Generally, threshold stimulation is
greater than 1.0 volt. Subthreshold stimulation refers to the
application of electrical stimulation to tissue at levels low
enough not to elicit a gross electrical or mechanical response from
the tissue, such as to not cause cardiac depolarization or muscle
contraction. A subthreshold stimulus can be achieved by keeping
either the voltage amplitude and/or the duration of the electrical
pulses below the threshold response levels for gross motor or nerve
responses. Generally, subthreshold stimulus is less than or equal
to 1.0 volt. Subthreshold stimulation allows one to deliver
electrical stimulation to the tissue to increase the levels of
angiogenic protein available without having the unwanted side
effects due to the stimulation of nerve or muscle cells, such as
unwanted contraction and or uncomfortable tactile sensations, and
the like.
[0045] As used herein, a number of terms for measured physical
parameters have been abbreviated: amplitude may be expressed in
volts (V) or millivolts (mV); current may be expressed in amperes
(amps) or milliamperes (mamps); and pulse width, frequency, or
timing in milliseconds (msec); and energy in joules (J) or
millijoules (mJ).
[0046] Description
[0047] In general the present invention relates to a subthreshold
pulse generator for producing an electrical field near to or within
a targeted body tissue and methods of treating damaged or ischemic
tissue by stimulating angiogenesis. In one embodiment the
electrical field is delivered directly to the target area located
between a plurality of electrodes. As an example, FIG. 1 (FIG. 1)
illustrates a subthreshold pulse generator (1) creating a
subthreshold electrical field (5) to the lower ventricle of the
heart (4) through a pair of leads (2) and electrodes (3).
[0048] Subthreshold stimulation has been demonstrated to promote
production of angiogenic growth factors. The promotion of
angiogenic response by the present device thereby serves as a
significant adjunct over current surgical methods of intervention
to re-establish circulation to ischemic tissue areas.
[0049] Purpose of the Subthreshold Pulse
[0050] The present invention provides a novel subthreshold
electrical pulse generator (also referred to herein as subthreshold
pulse generator, pulse generator, or generator). The pulse
generator has the essential feature of being capable of providing
an electrical stimulus or series of electrical subthreshold
stimulations or pulses (pacing). The subthreshold electrical
stimulus or pulses are used to induce angiogenesis in targeted
cells or tissues. In one embodiment, the electrical stimulator
provides a subthreshold stimulation to activate transcription of at
least one angiogenic factor. The objective of the subthreshold
stimulation is not to excite the tissue for mechanical contraction
but to selectively activate angiogenesis.
[0051] It is envisioned that different stimulation therapies may be
given in conjunction with a course of subthreshold stimulation
therapy. At times, particularly when considered with benefits of
threshold electrical stimulation of traditional pacemakers, it may
be advantageous to combine the features of a traditional pacemaker
with components for subthreshold stimulation.
[0052] Pulse Generator Operation Parameters
[0053] The controlled output voltage from the subthreshold
electrical pulse generator can be adjusted for a wide range of
tissue impedances, such as from 0.35 .OMEGA. to infinity. Through a
variety of unique combinations of voltage and timing settings the
present device provides a unique mechanism to increase production
of angiogenic factors while not evoking contractile responses.
[0054] The present generator allows the use of a constant voltage,
regardless of the distance between electrodes, by allowing a
variable field density. The present generator allows for control
over the amplitude of the voltage and for charge balancing of the
delivered and recovered charged pulse. As a specific embodiment,
the subthreshold pulse generator allows the use of a constant
voltage by allowing a variable field density of about 30% of the
targeted voltage, more preferably of about 20% of the targeted
voltage, and even more preferably of about 10%, and most preferably
of about 5% of the targeted voltage. As will be illustrated later,
the subthreshold voltage is at a constant level, allowing the field
intensity to vary across the tissue. Effective results were
obtained in the in vitro experiments having a variable field
intensity in vitro (see Experiment 1, Table 1) as well as with
stimulating VEGF production in vivo (see Experiment 2, FIG. 7).
[0055] In one embodiment, the subthreshold pulse generator is
capable of delivering an electric field to the targeted body tissue
of 0 to 1.5 V output in steps of 0.1 V, wherein the electric field
is generally less than or equal to about 1 V/cm, and more
preferably less than about 0.5 V/cm, and even more preferably about
0.1 V/cm.
[0056] In yet another embodiment, the subthreshold field can be
produced by a number of pulses with a frequency about 10 Hz to
about 100 Hz, and preferably with a frequency of about 25 Hz to
about 85 Hz, and more preferably with a frequency of about 40 Hz to
about 70 Hz, and even more preferably with a frequency of about 50
Hz to about 60 Hz, and most preferably with a frequency of about 50
Hz.
[0057] In a further embodiment, the stimulation period is less than
the pulse cycle (1/frequency). The stimulation period can be chosen
to be between about 100 msec and 0.01 msec, between about 50 msec
and 0.05 msec, and between 3 msec and 0.1 msec, wherein the actual
value can be less than about 20 msec, preferably less than about 10
msec, more preferably less than about 3 msec or any value between
0.1 ms and 3.0 ms.
[0058] Subthreshold Stimulation
[0059] The schematic of the output circuitry in FIG. 2 is a
simplified illustration of the schematic of the operating circuitry
for a subthreshold pulse generator. FIG. 2 is useful for setting
basic design requirements of a subthreshold pulse generator:
S.sub.1, S.sub.2, and S.sub.3 are switches that are opened and
closed during the operating cycle, R is a circuit resistor, Vs is
the battery, and C.sub.H and C.sub.C are capacitors. For example,
if the component values can be chosen as follows: VS=2.8 Volts,
R=25 .OMEGA., C.sub.C=C.sub.H=10 .mu.F, one can calculate that
C.sub.H will have 0.110 volts at the end of 10 msec charging phase
as shown in FIG. 4. By this illustration, one skilled in the art
could choose a number of settings that would provide C.sub.H at any
given set of subthreshold output voltages. FIG. 3 shows the
equivalent circuit of the output stage during the stimulation
phase. V.sub.C represents the initial condition on the C.sub.H.
[0060] In this case, because C.sub.H, C.sub.C and R.sub.tissue are
connected in series, one can combine C.sub.H and C.sub.C into
C.sub.eq=5 .mu.F. Voltages seen at the electrodes are given by:
V.sub.Tissue(t)=V.sub.CH(O) {1-exp[-t/(C.sub.EqR.sub.Tissue)]}. If,
for example, the output voltage is allowed to change by only 10%,
then the V.sub.Tissue(t) will vary between 0.110 volts and 0.090
volts. That would indicate that V.sub.CH(O)=0.110, and
V.sub.Tissue(t) (0.3 msec)=0.090. Rewriting the equation for the
tissue voltage, 0.090=0.110{1-exp[-t/(C.su- b.EqR.sub.Tissue)]},
t=0.3 msec or 0.090=0.110{1-exp[-0.3.times.10.sup.-3/-
(5.times.10.sup.-6.times.R.sub.Tissue)]} and solving for
R.sub.Tissue one can find that R.sub.Tissue=35 .OMEGA.. In other
words, the minimum tissue impedance that one can drive will be 35
.OMEGA., with output voltage staying in the 90-110 mV range. Use of
the above settings in the pulse generator provides one example for
(1) a pulse generator for subthreshold stimulation; (2) controlled
output voltage for a wide range of tissue impedances (35 .OMEGA. to
infinity); (3) a pacing output for subthreshold stimulation where
the objective is not to excite the tissue for mechanical
contraction but to increase the amounts of angiogenic factors
available by providing a set of variables equal to or less than a
1.0 volt subthreshold stimulus.
[0061] FIG. 4 (FIG. 4) exemplifies a set of subthreshold
stimulation parameters. FIG. 4. illustrates the timing diagram of
the electrical pulses and charging of capacitors, to provide the
illustrated pulse train: pulse frequency of 50 Hz (20 msec);
stimulatory pulse of 0.3 msec to the tissue (Vtissue) and a 6.7
msec discharge (recharge with opposite polarity for charge
balance). The remaining 13 msec of the pulse cycle electrodes are
floating, and capacitors are recharged.
[0062] FIG. 5. (FIG. 5) is a block diagram of a subthreshold
stimulator employed in chronic animal studies. The basic stimulus
repetition frequency of 50 Hz is generated by the clock/timer at
upper left. This triggers timers that control the 1 msec discharge
and 5 msec recharge phases of each output pulse (top center). Pulse
amplitude is controlled by 4-bit DAC (left center). The pulse
output circuit (center) utilizes the timing and amplitude
information to generate the actual output pulse which is, in turn,
delivered to electrodes and the tissue (right center). The pulse
output circuit (bottom center) optionally incorporates a lead
continuity monitor to check for lead or electrode malfunction.
Output amplitude may be adjusted (dashed line) based on conditions
of increased electrode resistance, or turned off if a lead breaks
or shorts. An alternative stimulation setting of 2 Hz (upper left)
is employed for evaluation of the stimulation safety margin (pacing
threshold) in conjunction with the output amplitude control.
[0063] FIG. 6 (FIG. 6) shows the stimulator circuit used during in
vivo experiments. Explanations of general symbols used in the
circuit diagram are as follows:
[0064] U: Integrated Circuit
[0065] R: Resistor
[0066] C: Capacitor
[0067] SW: Switch
[0068] D: Diode
[0069] Vcc: Positive terminal of the power supply (battery)
[0070] Vee: Negative terminal of the power supply (battery)
[0071] JP: Jumper terminal for off-board connections
[0072] Below is a list of components labeled specifically:
[0073] (1) U2: Main oscillator keeping the stimulator timing at 50
Hz (20 milli-seconds)
[0074] (2) U1B: Timer to control the stim pulse width, which closes
S2 shown as (13).
[0075] (3) U1A: Timer to control the discharge duration, which
closes S3, shown as (7).
[0076] (4) C11 is the holding capacitor, C.sub.H, with the value of
10 micro-Farads.
[0077] (5) C10 is the coupling capacitor, C.sub.C, with the value
of 6.8 micro-Farads.
[0078] (6) JP2 is the header where the stimulation electrodes are
attached.
[0079] (7) U5: Switch S3, when closed discharges the coupling
capacitor.
[0080] (8) R9: Resistor in series with the tissue being stimulated
that is used to measure the stimulation current intensity.
[0081] (9) SW2: Switch to test lead integrity using the lead
integrity indicator shown as (10)
[0082] (10) LED: Light emitting diode used as lead integrity
indicator
[0083] (11) U7C: Digital to analog converter which is used to set
the stimulation amplitude, Vadj, shown as (14).
[0084] (12) U7D: Inverter/driver for the adjustable stimulation
amplitude determined by (11).
[0085] (13) U3: Switch S3, when closed, delivers charge from the
holding capacitor to the tissue connected to (6).
[0086] (14) Vadj: adjustable stimulation amplitude determined by
(11)
[0087] The subthreshold stimulator circuit of FIG. 6A (FIG. 6A) and
continued on FIG. 6B (FIG. 6B) operates essentially to produce the
stimulation waveform shown in FIG. 2. The generated stimulus is a
periodic signal which main oscillator (1) is set to produce 50 Hz
digital pulses, and provides the main clock. Timers (2) and (3)
produce the stimulation and discharge pulses, respectively, from
the clock, again as shown on FIG. 2. These pulses are used to close
the switches (13) and (7), which correspond to S.sub.2 and S.sub.3
on FIG. 2. Terminals 1 and 4 of the on board connector (6) is where
the leads going to the tissue are attached. During the stimulation,
energy stored on holding capacitor (6) passes through switch (13),
the coupling capacitor (5), and series resistor (8) to reach
terminal (6) before arriving at the tissue. Voltage drop on series
resistor (8) can be monitored from terminal (6) to get an
indication of the current being passed through the tissue. Switch
(9) can be used to monitor the lead integrity using the lead
integrity indicator (10). Stimulation amplitude adjuster (14) is
set by the digital to analog converter (11) followed by the
inverter/driver (12).
[0088] Additional Features of the Subthreshold Pulse Generator
[0089] In another embodiment, the subthreshold pulse generator can
be used externally, but preferably is designed and configured to be
implantable. The present device can be implanted into the body and
the electrical components sealed from the body tissues and fluids.
Ideally, the implantable device has a volume of about 50 cm.sup.3,
preferably about 40 cm.sup.3, more preferably about 30 cm.sup.3,
even more preferably about 20 cm.sup.3, and most preferably about
10 cm.sup.3.
[0090] It is envisioned that the electrical pulse generator can be
implanted or can be external to the body. Ideally, the subthreshold
pulse generator is implanted.
[0091] Electrodes and Leads
[0092] The subthreshold pulse generator includes a power supply and
a control mechanism interconnected with the power supply.
Optionally, the pulse generator can be used with electrodes in
electrical communication with the power supply. In another
embodiment he subthreshold stimulation provided is sufficient to
stimulate angiogenesis in the targeted body tissue. The present
generator is also capable of checking the lead continuity at a
predesignated time. In other preferred embodiments, electrodes and
leads can be used with the subthreshold pulse generator. In a
preferred embodiment, the electrodes are configured in a manner
consisting of bipolar or multiple electrode configurations.
[0093] The electrodes are made of conductive metals or organic
polymers, or combinations of the two. For example, they can be made
of platinium, gold, zirconium, iridium, titanium, certain carbons,
stainless steel, silver, copper, tin, nickel, iron, or lithium, or
various mixtures, alloys, or amalgams thereof. Design of the
electrodes can take on a number of different shapes and sizes,
depending oh the nature of the target tissue. In the case of heart
muscle or other muscle tissues, the electrodes can consist of a
straight pin, screw, patch, or the like, which can further comprise
various barbs, hooks, or alternate structures for affixing the
electrode.
[0094] As yet another embodiment, various types of electrical leads
similar to those exemplified herein or commonly used with other
implantable pulse generators can be used to connect to the power
source.
[0095] A number of suitable electrodes can function to provide the
electrical stimulation. In one feature, the electrode is a surface
coil electrode, or heart wire. The surface electrode may be
constructed of a platinum alloy or other biocompatible metals. The
electrode can be a coil, a cylinder, a wire, or any other
shape.
[0096] Electrode placement can be done in one of two ways: In the
preferred embodiment, electrodes are advanced to the vicinity of
the tissue of the heart where the angiogenesis is desired, using
the venous system, and left in place. Alternatively, it is possible
to place the electrodes in place using minimally invasive surgical
procedures, which would allow access to locations that are beyond
the reach of the catheters in the vasculature. In either case,
bipolar or unipolar stimulation can be applied to generate the
electrical fields in the tissue to trigger the electrically
responsive promoter. Bipolar stimulation is the preferred
method.
[0097] The placement of the electrodes would be determined
primarily by the method used to implant the electrodes. If the
electrodes are placed via a transvenous route then the electrodes
should be placed as close as possible to the implanted cells,
ischemic tissue, or target area for angiogenesis, understanding
that patient anatomy may not allow close proximity of the
electrodes. If a non-transvenous implant technique is used, then
the stimulating electrodes can usually be placed very close to the
ischemic area.
[0098] Subthreshold Stimulation of Patients and Cells
[0099] The subthreshold stimulation provided is sufficient to
stimulate angiogenesis in the targeted body tissue of a patient. As
one embodiment, the pulse generator is used to modulate
transcription of angiogenic growth factors by the delivery of
subthreshold electrical fields.
[0100] The invention also provides a subthreshold pulse generator
for a patient in need of subthreshold stimulation therapy. In one
embodiment, the invention includes a method for reducing or
repairing tissue injury by providing a means for regulating
angiogenic growth factor production. In one aspect the pulse
generator is effective in delivering subthreshold pulses that
mediate the repair of injured muscle tissue, such as where ischemic
injury has occurred. The method may be applied to damaged cardiac
or peripheral muscle tissue by providing a therapeutic stimulus to
the surrounding cardiac or muscle tissue or cells. In an
alternative embodiment, vascular muscle tissue is stimulated using
the subthreshold pulse generator. Subthreshold stimulation of
vascular tissue includes stimulation of arteries and veins in a
patient.
[0101] In one feature of the invention, the present system can be
used to treat peripheral arterial occlusive disease (PAOD) or
coronary arterial disease (CAD) or stroke, by delivery of a
therapeutically effective amount of subthreshold stimulation. It is
envisioned that treatment of peripheral arterial occlusive disease
(PAOD) or coronary arterial disease (CAD) is achieved by
stimulation of angiogenic proteins, such as VEGF and FGF, to
enhance blood vessel formation (angiogenesis).
[0102] The present invention also provides a novel method of
stimulating cells for controlled expression of angiogenic factors.
In one preferred embodiment the stimulated cells are muscle cells.
In another preferred embodiment the cells are muscle cells, and
more preferably, heart, smooth, or skeletal muscle cells. As a
preferred embodiment, subthreshold pulses are proved to enhance the
cellular production of endogenous angiogenic growth factors of the
transplanted cells. In an alternative embodiment, the present
device can be used in vitro to pre-stimulate cells which may then
be transplanted to the heart. In this process, cells in culture are
stimulated in a subthreshold field and used for transplantation. In
this process cells may be taken from the patient (autologous cell
transplantation) or used from a different patient of the same
species (allogenic cell transplantation) or from a different
species (xenogenic cell transplantation).
[0103] Transplanted cells or grafts may be derived from auto-,
allo- or xeno-graphic sources. Transplanted or grafted cells for
heart tissue used with pre- or post subthreshold stimulation can be
chosen from the group consisting of adult cardiomyocytes, pediatric
cardiomyocytes, fetal cardiomyocytes, adult fibroblasts, fetal
fibroblasts, adult smooth muscle cells, fetal smooth muscle cells,
endothelial cells, and skeletal myoblasts (see U.S. Pat. No.
6,099,832 and procedures described herein for isolation of various
cell types). A number of additional procedures are known and
described in the art for isolating various primary cell types.
EXAMPLES
[0104] The present invention is further described by the following
examples. The examples are provided solely to illustrate the
invention by reference to specific embodiments. These
exemplifications, while illustrating certain specific aspects of
the invention, do not portray the limitations or circumscribe the
scope of the invention.
[0105] Materials and Assays
[0106] Human VEGF in samples was quantified using the Human VEGF
Immunoassay by Quantikine.RTM.. The protocol followed was
essentially as described in the Quantikine.RTM. Catalog (Number
DVE00). The Human VEGF Immunoassay employs a sandwich enzyme
immunoassay technique. A monoclonal antibody specific for VEGF is
pre-coated on micro-titer plates. Standards and samples are
pipetted into wells and any VEGF present is bound by the
immobilized antibody. After washing away any unbound substances, an
enzyme-linked polyclonal antibody specific for VEGF is added to the
wells. Following a wash to remove any unbound antibody-enzyme
reagent, a substrate solution is added to the wells and color
develops in proportion to the amount of VEGF bound in the initial
step. The color development is stopped and the intensity of the
color is measured.
Example 1
[0107] Sterile 6 well culture plates (Corning) were seeded with
cells on six well culture inserts using SmGM growth media;
C.sub.2C.sub.12 cells (mouse myoblasts) were seeded at
7.5.times.10.sup.3/cm.sup.2; Human Coronary Smooth Muscle Cells
(HCASMC) were seeded at 2.5.times.10.sup.3/cm.sup.2. After two
days' growth (confluent), the wells were washed twice with
electrical stimulation medium (DMEM with 1% bovine serum albumin).
2.0 ml of serum free medium was added but without any fetal bovine
serum in the medium. Wells contained approximately 4 ml of total
growth medium, approximately 2.0 ml inside well insert and 2.0 ml
outside well insert. The cells were electrically stimulated using a
circular graphite electrode for 8 hours per stimulation condition.
Cells were stimulated at one volt in the stimulation chamber for 1
msec stimulation pulse width with a 4 msec discharge pulse width.
The escape period was adjusted to achieve the desired frequency.
Samples were harvested after 22 hours post-stimulation. Cell
culture supernatants were removed from the well. Any debris or
floating cells were removed by centrifuging the supernatants at 300
RPM for 5 minutes prior to freezing the samples at -85.degree. C. A
cell count was done on all wells of the culture plate.
[0108] Frozen supernatants were thawed and quantified for the
amount of VEGF in the samples using the Quantikine Human VEGF
Immunoassay. The results (Table 1) indicated that subthreshold
stimulation increased the amount of VEGF found in the samples.
1 TABLE 1 Cells Control 24 Hz 50 Hz (seeding density) (pg/10.sup.3
cells) (pg/10.sup.3 cells) (pg/10.sup.3 cells) C.sub.2C.sub.12 0
.104 .0556 HCASMC (2 .times. 10.sup.4) 0.410 0.360 0.670 (4 .times.
104) 1.920 1.920 3.140
Example 2
In Vivo Subthreshold Stimulation in Canine Model of Regional
Ischemic Cardiomyopathy
[0109] Dogs were initially anesthetized with intramuscular morphine
sulfate (4 mg/kg)/A bolus injection of pentothal (20 mg/kg) was
given followed by continuous inhaling of isoflurane (0.5%-2% in
oxygen) after endotracheal intubation. A left lateral thoracotomy
was performed, and the pericardium opened. A micromanometer
pressure transducer (MPC-500, Millar Instruments, Houston, Tex.)
was inserted into the left ventricle through an apical incision.
Pairs of 5 MHz ultrasonic crystals also was implanted in the area
supplied by the distal left anterior descending (LAD) and left
circumflex (LCX) arteries just distal to the first diagonal branch
of measurement of coronary flow. Two heart wire electrodes were
inserted in the LAD perfusion area. A catheter was inserted into
the left atrium for injection of colored 15 um microspheres to
measure regional myocardial blood flow. Ameriod constrictors were
placed on the LAD artery proximal to the flow probe. All wires and
tubing were tunneled subcutaneously and brought out through the
skin of the dorsal neck. The thoracotomy incision was closed in
layers, and a regimen of broad spectrum antibiotics and analgesia
was initiated throughout the reperfusion period.
[0110] The basic chronology of the experimental protocol after
surgery was divided into three periods. The first period (recovery
period) occurred in the first week after surgery. After surgery to
instrument the dogs, the dogs were allowed to recover. During week
one, microspheres were injected for evaluating resting coronary
blood flow (CBF) at one week. The second period occurred during
weeks 2 through 5 after surgery, and included weekly monitoring of
regional stroke work, CBF (LAD and LCX), and left ventricular
pressure (LVP) in addition to microsphere injections for evaluating
resting CBF. The third period, week 5 through 6 the stimulation
occurred for 5 days.
[0111] During the six week period, all hemodynamic signals were
recorded using an analog-digital converter with sampling at 250 Hz.
Regional blood flow was assessed using colored microspheres (15 uM)
to quantify the blood flow in the epi- and endomyocardium at the
end of the recovery phase (first period), following development of
ischemia (second period), and following field stimulation (third
period). Tissue and reference blood samples were analyzed in a
Spectra Max 250 Microplate Reader Spectrophotometer. Myocardial
blood flow was calculated in the subepicardial and subendocardial
region of nonischemic and ischemic zones. The potential loss of
microspheres from chronic postischemic tissue is corrected by using
a rate factor of baseline flow in nonischemic tissue applied to
ischemic tissue blood flow data (e,g, ischemic/nonischemic
flow).
[0112] At the start of week 6 subthreshold pulsing was delivered to
the heart using a subthreshold stimulator operated at 50 Hz, 0.1 V,
with 0.3 ms pulses. The subthreshold stimulator had an operational
range of 0 to 1.5 V output in steps of 0.1 V for all 16 allowed
settings, pulse widths of 0.1, 0.3, 1.0, and 3.0 m by a series of 4
slide switches. As a result of this pulse output flexibility, the
stimulator also had the ability to determine pacing threshold and
thus the margin or extent to which the 0.1V, 50 Hz pulses are
subthreshold. This is done by setting the device to an assessment
mode of 1-3 Hz while stepping up the amplitude to look for VOO
pacing capture. Stimulation was delivered via a set of myocardial
pacing wires or "Heart-Wires" that were connected to the stimulator
through a set of unipolar IS-1 leads to a biopolar IS-1 connector.
In addition, the pulse generator contains a combination battery
level OK and pacing wire continuity OK indicator with a visible LED
light.
[0113] The LAD heart area was stimulated for 5 days during week six
before terminating the experiment. Sample heart tissue was
collected from both stimulated and unstimulated dogs. Heart tissue
samples were taken and prepared for Western blot analysis using a
VEGF antibody (FIG. 7). Total protein was extracted from
postexperimental cardiac tissue. 100 ug of protein was loaded onto
each lane of a SDS-Page gel, and run for 15 minutes at 200 Volts.
The lanes were exposed to a polyclonal antibody for human VEGF
(Santa Cruz). This antibody was blocked by a molecule that blocks
the antibody's binding epitope (data not shown), and hence is
specific for the VEGF site. Lane 8-11=control group. Lane 8
(nonischemic transmural); Lane 9 (ischemic subepicardium); Lane 10
(ischemic subendocardium); Lane (right ventricle); Lanes 12-15 are
treatment (field stimulation) group: Lane 12 (transmural
nonischemic); Lane 13 (ischemic subepicardium); Lane 14 (ischemic
subendocardium); Lane 15 (right ventricle). Bands for VEGF appear
at approximately 26 kD molecular weight. Two bands appear, typical
of the two fragments seen for VEGF. Notice that bands consistent
with VEGF appear only in Lanes 12-15, i.e. in the treated group.
Gels were processed on the same day to avoid variability.
* * * * *